Results
Filtros
Anvisa rectifies RDC No. 1,015 and adjusts labeling rules for cannabis products
Correction published in the Official Gazette clarifies requirements on packaging and maintains authorization for magistral manipulation of CBD
Anvisa may vote on maintaining or removing the agenda item for the review of RDC 327/2019, which regulates medicinal cannabis products
The item revising RDC 327/2019 reaches a decisive week at Anvisa, and the sector awaits to know if the topic will proceed to a vote or be postponed once again
Anvisa removes the revision of RDC 327/2019 from the Collegiate Board meeting agenda
Update of the RDC included in the Regulatory Agenda 2024-2025 is expected for next year
Follow Live: Anvisa now debates review of RDC 327 and cultivation
Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Follow Live: Anvisa now debates revision of RDC 327 and cultivation
Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Anvisa to decide today the future of RDC 327 in a meeting that could redefine rules for cannabis products in Brazil
Norm that regulates manufacturing, importation, prescription, and inspection may be entirely revoked and replaced by a new regulatory framework; decision will be made at the Collegiate Board meeting.
Anvisa publishes proposal to update RDC 327 redefining rules for cannabis products in Brazil
Draft presents new regulatory framework, tightens requirements for Sanitary Authorization, and prohibits manipulation of cannabis derivatives
What can change in the cannabis market after the end of sanitary authorization of RDC 327?
Free webinar will clarify Medicinal Cannabis Regulation in Brazil
"Legally consolidates what had already been built," says veterinarian about new Anvisa regulation
Caroline Campagnone views RDC 999/2025 favorably, allowing veterinarians authorized by CFMV to prescribe medical cannabis
“It is important that the compounding pharmacy has access to all cannabis inputs" argues Marco Fiaschetti, from Anfarmag
With the revision of RDC 327/2019, compounding pharmacies gain space in the discussion on medicinal cannabis
Anvisa updates control of substances and redefines rules for medicinal cannabis
New RDC No. 1,011 expands regulatory details on Cannabis derivatives, medicinal products, and pharmaceutical inputs
What to Expect This Year in the World of Cannabis?
01/13/2023We should witness changes in RDC 327, flexibility in the pharmaceutical form of products, a new resolution from CFM, but this agenda is unlikely to progress in Congress.
Anvisa discusses review of regulation of medicinal cannabis products
Public consultation proposal for the review of RDC No. 327/2019 will be evaluated by the Collegiate Board on December 19, 2024
Ease Labs: Brazilian laboratory specialized in cannabis stands out in pharmacies across the country
The Minas Gerais-based company, which also studies psychedelic compounds, establishes itself as one of the leading names in the sector via RDC 327
Medical cannabis and compounding pharmacies: Anfarmag's position
In Deusa Cast #54, Marco Fiaschetti advocates for treatment customization and the inclusion of the compounding model in the revision of RDC 327
Anvisa Collegiate Board has new composition defined after director's departure
Marcelo Mario Matos Moreira assumes as substitute in the Fourth Board, filling the vacancy of the former rapporteur of the review of RDC 327
With partnerships, NHG Phytopharmaceuticals and Nutraceuticals seeks to structure itself for the Brazilian market
03/10/2021The company, headquartered in Campinas, wants to take advantage of the path paved from RDC 327 and establish itself as an alternative in the Brazilian medicinal cannabis market with the development of studies, product launches, and, who knows, in the supply
CFF advocates for magistral manipulation amid changes in Cannabis regulation
Entity reinforces that personalized preparations are essential when industrialized products do not meet clinical needs
Regulation of Cannabis Products for Medicinal Purposes Enters Anvisa's Regulatory Agenda 2024-2025
Review of the Brazilian Pharmacopoeia collegiates is also included in the Agenda
Anvisa proposes strict rules for cannabis cultivation for research purposes in Brazil
New resolution allows planting by universities and pharmaceutical industries, requiring maximum security systems and total traceability of the plant